TEM slides nearly 8% as price action diverges from strong technical momentum and positive news

Traders Union
All News
Stocks
Tempus AI slides 7.63% today

Highlights

Tempus AI received FDA 510(k) clearance for two AI cardiovascular analysis tools and secured a $42 million data licensing extension with Recursion Pharmaceuticals.
The company reported annual revenue of $1.27 billion and a net loss of $245.03 million, alongside recent Wall Street upgrades and new partnership announcements.
Shares of Tempus AI showed a sharp intraday decline of 7.63% with technical signals indicating prevailing bullish momentum and a probable range of $72.1 to $87.22 for the next five days.

FDA clearance and partnerships bolster fundamentals amid persistent selloff

Tempus AI received FDA 510(k) clearance for its ECG-MR and ECG-PH AI-powered cardiovascular analysis tools. The company extended its data licensing partnership with Recursion Pharmaceuticals, securing $42 million in committed license payments through November 2029. Annual revenue of $1.27 billion and a net loss of $245.03 million were reported, with these milestones accompanied by recent Wall Street upgrades and new partnership developments, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees the abrupt drop in Tempus AI as a concerning signal. He notes that the decline occurred despite strong technicals and recent positive news flow, such as the FDA clearance and extended data partnerships. Kharitonov is wary of the company’s persistent net losses and broader selling pressure clouding bullish momentum. He emphasizes that short-term traders should not ignore the sharp downside gap, which may point to deeper risks. "I remain cautious here — the fundamentals are not supportive enough to justify chasing strength while selling pressure intensifies."

Viktoras Karapetjanc, expert at Traders Union, highlights the robust underlying structure for Tempus AI. He believes the FDA clearance and long-term partnership with Recursion Pharmaceuticals firmly strengthen the growth outlook. Karapetjanc notes resilient annual revenues and ongoing Wall Street optimism despite recent volatility. He sees the technical alignment above key moving averages as a foundation for further upside. "This market offers multiple setups for bullish continuation — I expect further growth as the company's innovation attracts more attention."

Jainam Mehta, market strategist, views the recent drop as a classic case of momentum divergence against strong technical support. He notes that short-term weakness could set up a tactical opportunity if support at $76.46 holds. Mehta sees consolidative price action as a zone for possible contrarian entries, especially if sentiment remains negative despite bullish signals. "A sustained bounce from present levels could trigger a fast move toward resistance, so I would watch closely for reversal patterns here."

Bullish momentum persists despite overbought signals and daily drop

Tempus AI trades above its 20-day, 50-day, and 200-day moving averages at $74.4, $63.38, and $56.52, respectively. This alignment reflects short-, medium-, and long-term bullish structure. Current trading is defined by resistance at $83.85 and support at $76.46, while the Ichimoku Kijun at $73.32 provides additional support and the MA-50 and MA-200 confirm prevailing long-term strength. Momentum remains positive: the MACD signals a strong buy, and the ADX above 30 reinforces the overall bullish environment. The RSI, Stochastic RSI, and CCI all indicate sustained buying interest, but the Bull/Bear Power indicator suggests buyers are dominant and the stock is entering slightly overbought territory. Despite these signals, the stock fell sharply on the day, opening with a significant downside gap and closing near intraday lows, signaling negative pressure against an otherwise positive trend.

Previously it was reported that Tempus AI maintained a strong bullish technical structure supported by sustained upward momentum. While the current article highlights a sharp daily decline amid negative price action despite favorable fundamentals and technicals, traders should closely monitor the $76.46 support as a potential trigger for short-term downside risk should selling pressure persist.

Source of Data: TEM Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.